Intended use: Proactive utilization of the assay for pretreatment with monoclonal antibody therapies (mAB) (CD38/47) or other interfering agents, prospective antigen matching for multiply transfused patients with hemoglobinopathies (eg, sickle cell), and serological testing complications due to prospective or recent transfusion and/or autoantibodies. BGG Navigator testing provides a single efficient multiplex test to determine the blood group antigen profile of a patient either before treatment begins or even after anti-CD38/47 therapy has been initiated.
Proactive genotyping (FDA Approved)
Improve outcomes, patient experience and drive efficiency at a lower cost in patients receiving monoclonal antibody therapy and cruise through complex Hematologic Malignancies, Hemoglobinopathies, and Sickle Cell Disease testing with BGG Navigator.

This information is for US physicians and healthcare professionals only.

Optimize patient care with BGG Navigator
Unite oncology, transfusion medicine, and pharmacy with a simple proactive blood group genotyping test. For oncology patients with anemia, hematologic malignancies and other choronic conditions, there's no alternative to lifesaving blood transfusions. With BGG Navigator, send your samples to the Grifols Laboratory Solutions for a simple proactive blood group genotyping test that improves confidence for less.

Proactive pretransfusion testing with BGG navigator
Maneuver through pretransfusion testing and interference of monoclonal antibody therapies with ease and address the challenges of delivering optimal patient care for patients that need you most with a single test we perform for patients treated with anti-CD38/47 prior to, or after therapy has been initiated.
One test, better outcomes
Rethink how you manage pretransfusion testing with monoclonal antibody interference.
Implement BGG Navigator
Follow these four easy steps for successful implementation at your institution.